Exosomal biomarkers represent an emerging class of molecular indicators found within extracellular vesicles (EVs), specifically exosomes. These small membrane-bound vesicles (30-150nm) are secreted by all cell types, including neurons and glial cells, and carry a cargo of proteins, lipids, RNA, and DNA that reflects their cellular origin. In neurodegenerative diseases, exosomal biomarkers offer a promising window into brain pathology through peripheral biofluids. [1]
| Protein | Disease | Source | Key Findings | [2]
|---------|---------|--------|--------------| [3]
| Aβ1-42 | AD | Neuronal exosomes | Elevated in AD vs controls | [4]
| Total tau | AD | Neuronal exosomes | Higher in AD | [5]
| Phosphorylated tau | AD | Neuronal exosomes | p-tau181, p-tau231 elevated | [6]
| α-Synuclein | PD/DLB/MSA | Neuronal exosomes | Elevated in synucleinopathies | [7]
| TDP-43 | ALS/FTD | Neuronal exosomes | Increased in disease |
| HTT | HD | Neuronal exosomes | Mutant HTT detectable |
| miRNA | Disease | Target | Clinical Utility |
|---|---|---|---|
| miR-132 | AD | Synaptic function | Decreased in AD |
| miR-124 | AD/PD | Neuronal development | Reduced in disease |
| miR-153 | AD | APP processing | Downregulated |
| miR-7 | PD | α-synuclein | Reduced in PD |
| miR-29 | AD | BACE1 | Decreased in AD |
| Application | Biomarker | Sensitivity | Specificity |
|---|---|---|---|
| AD vs controls | Neuronal exosome Aβ42 | 85-95% | 80-90% |
| AD vs FTD | Neuronal exosome p-tau181 | 90% | 85% |
| PD vs controls | Neuronal exosome α-syn | 80-90% | 75-85% |
| PD vs MSA | α-syn species | 75% | 80% |
| Region | Status | Notes |
|---|---|---|
| FDA | LDT pathway | Available through certified labs |
| CE | IVD certified | EU approved assays |
| PMDA | Research use only | Japan |
| NMPA | Emerging | China - several trials |
| KFDA | Research use only | Korea |
Exosomal biomarkers have been validated in multiple Asian population studies:
The study of Exosomal Biomarkers In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Shi M, et al. Exosomal α-Synuclein in Parkinson's Disease. 2023. ↩︎
Goetzl EJ, et al. Exosome Biomarkers in Neurodegeneration. 2024. ↩︎
Stuendl A, et al. Induction of Exosomal α-Synuclein. 2023. ↩︎
Zlatanov IV, et al. Exosomal miRNA in AD. 2024. ↩︎
Spawner S, et al. Exosomes in ALS. 2023. ↩︎
Hong S-Y, et al. Exosomal Biomarkers for HD. 2024. ↩︎
Rajendran L, et al. Exosome Biology in Neurodegeneration. 2023. ↩︎
Cheng Y, et al. Exosomal biomarkers in Chinese AD cohort. 2024. ↩︎
Kim J-S, et al. Neuronal exosomes in Korean PD. 2024. ↩︎
Tanaka R, et al. Exosomal biomarkers in Japanese populations. 2023. ↩︎